At the European Society for Medical Oncology Congress 2022, Dr. Rugo presented results from the TROPiCS-02 trial, which was looking to see if the targeted therapy Trodelvy could offer more benefits for people diagnosed with previously treated, metastatic, hormone receptor-positive, HER2-negative breast cancer than chemotherapy. Currently, Trodelvy is approved to treat previously-treated, metastatic triple-negative breast cancer. Listen to the episode to hear Dr. Rugo explain: the type of medicine Trodelvy is and how it works the results showing people diagnosed with previously treated, metastatic, hormone receptor-positive, HER2-negative breast cancer lived longer when they received Trodelvy compared to chemotherapy how the results from TROPiCS-02 fit into current treatment options

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related